Astemizole; Terfenadine/Selected QT Prolongers
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Astemizole and terfenadine can affect your heart's rhythm. Other drugs can have the same effect.
What might happen:
Taking astemizole or terfenadine with other agents that can affect your heart rhythm may increase your risk of an irregular heartbeat, which may be life-threatening.
What you should do about this interaction:
Let your healthcare professionals (e.g doctor or pharmacist) know that you are taking these medications together. Your doctor may want to perform an electrocardiogram (ECG) on you to check your heart's rhythm. Let your doctor know right away if you notice an irregular heartbeat or have any dizziness or fainting episodes.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
References:
1.Apokyn (apomorphine hydrochloride) US prescribing information. Tercica, Inc. July, 2010.
2.Sprycel (dasatinib) US prescribing information. Bristol-Myers Squibb Company October, 2011.
3.Anzemet (dolasetron mesylate) US prescribing information. Sanofi-Aventis Us.S. LLC September, 2011.
4.Toviaz (fesoterodine) UK summary of product characteristics. Pfizer Limited February, 2011.
5.Foradil Aerolizer (formoterol fumarate) US prescribing information. Schering Corporation September, 2012.
6.Symbicort Turbuhaler (budesonide-eformoterol fumarate dihydrate) Australian prescribing information. AstraZeneca Pty Ltd April 30, 2004.
7.Primovist (gadoxetate disodium) Australian prescribing information. Schering-Plough Corporation November 1, 2005.
8.Primovist (gadoxetic acid) UK summary of product characteristics. Bayer plc May 1, 2008.
9.Tequin (gatifloxacin) US prescribing information. Bristol-Myers Squibb Company January, 2006.
10.Factive (gemifloxacin mesylate) US prescribing information. Oscient Pharmaceuticals October, 2011.
11.Serenace (haloperidol) Australian prescribing information. Sigma Pharmaceuticals Pty Ltd. June 5, 2001.
12.Dozic (haloperidol) UK summary of product characteristics. Rosemont Pharmaceuticals Limited September 10, 2007.
13.Haldol (haloperidol) US prescribing information. Ortho-McNeil-Janssen Pharmaceuticals, Inc. August, 2011.
14.Tykerb (lapatinib) US prescribing information. GlaxoSmithKline February, 2012.
15.Levaquin (levofloxacin) US prescribing information. Ortho-McNeil Pharmaceutical, Inc. Apil, 2012.
16.Dolophine (methadone hydrochloride) US prescribing information. Roxane Laboratories, Inc. July, 2012.
17.NegGram (nalidixic acid) US prescribing information. Sanofi-Synthelabo, Inc. November, 2012.
18.Noroxin (norfloxacin) US prescribing information. Merck & Co., Inc. March, 2013.
19.Aloxi (polonosetron hydrochloride) US prescribing information. MGI Pharma September, 2007.
20.Votrient (pazopanib) US prescribing information. GlaxoSmithKline November, 2012.
21.Edurant (rilpivirine) US prescribing information. Tibotec Pharmaceuticals December, 2012.
22.Risperidal (risperidone) UK summary of product characteristics. Janssen-Cilag, UK Limited May 14, 2004.
23.Trisenox (arsenic trioxide) US prescribing information. Cell Therapeutics, Inc. March, 2001.
24.Cipro (ciprofloxacin hydrochloride) US prescribing information. Bayer Corporation January, 2013.
25.Ciproxin (ciprofloxacin hydrochloride) UK summary of product characteristics. Bayer plc April 13, 2010.
26.Halaven (eribulin mesylate) US prescribing information. Eisai, Inc. November, 2010.
27.Trobalt (retigabine) UK summary of product characteristics. GlaxoSmithKline UK March 28, 2011.
28.Ablavar (gadofosveset trisodium) US prescribing information. Lantheus Medical Imaging, Inc. December, 2010.
29.Ranexa (ranolazine) UK summary of product characteristics. A. Menarini Pharma U.K. S.R.I. October 30, 2008.
30.Ranexa (ranolazine) US prescribing information. CV Therapeutics, Inc. July, 2011.
31.Istodax (romidepsin) US prescribing information. Celgene Corporation September, 2011.
32.Tikosyn (dofetilide) US prescribing information. Pfizer Inc. February, 2011.
33.Betapace (sotalol hydrochloride) US prescribing information. Berlex Laboratories August, 2011.
34.Vibativ (telavancin) US prescribing information. Astellas Pharma US, Inc. September, 2009.
35.The University of Arizona Center for Education and Research of Therapeutics. Drugs with Risk of Torsades de Pointes and Drugs with Possible Risk of Torsades de Pointes. Available at:http://www.crediblemeds.org/. Updated March 14, 2013.





